F.D.A. Approves Moderna’s mRNA Flu Vaccine

Reversing an earlier refusal, the FDA has approved Moderna's first mRNA flu shot for adults 50 and older. Here's what the major decision means as Health Canada considers its own approval of the vaccine.

The Food and Drug Administration's approval of an mRNA vaccine for flu comes after the agency initially refused to review the approval request for the shot.

The first mRNA-based flu shot to be approved by the Food and Drug Administration will be ready for the upcoming flu season. Moderna, the vaccine's maker

Moderna's new flu vaccine, mFLUSIVA, is approved for all adults ages 50 and up.

The shot, named mFlusiva, is intended for adults age 50 or older. Moderna said late Wednesday that it expects some of its new version to be available soon at select retailers.

The mFlusiva vaccine for older people is the first made with the mRNA platform key to ending the coronavirus pandemic The Food and Drug Administration has approved a new kind of flu vaccine for older people, the first made with the same mRNA technology that was key to ending the…

The flu shot, mFlusiva, was shown in a clinical trial to be up to 27 percent more effective than a standard flu jab

The Food and Drug Administration (FDA) late Wednesday approved the nation's first mRNA flu vaccine, manufactured by drugmaker Moderna. The agency approved the shot for two separate age groups; people age 50 to 64, and for 65 years and older. Moderna said it will conduct a…

The shot, mFlusiva, was given a traditional approval for adults ​aged 50 to 64, and an accelerated approval ⁠for those 65 years and older

The Food and Drug Administration approved Moderna's mRNA seasonal flu vaccine on Wednesday.

The Food and Drug Administration on Wednesday approved the U.S.’s first flu shot that uses mRNA technology: mFlusiva, from drugmaker Moderna.

The agency had initially refused to even review the application but reversed course after a public outcry.